Remdesivir could be approved very soon for COVID-19

Ross J Burland FXStreet

The hunt is on for a cure and vaccines for COVID-19. Piper Sandler says Remdesivir could be approved very soon for COVID-19.

Earlier in the month, Pfizer Inc was reported to be considering a collaboration with German drugmaker BioNTech SE to develop vaccines for COVID-19 using BioNTech's mRNA-based drug development platform, Pfizer's R&D head told Reuters on Thursday.

Reuters reported that Pfizer Chief Scientific Officer Mikael Dolsten was one of the pharmaceutical executives who attended a meeting with US President Donald Trump to discuss possible vaccines and treatments for the fast-spreading virus at the start of this month.

"Dolsten also gave more details about the company's efforts to develop potential anti-viral treatments for the virus, which are currently being screened by a third-party company to see how it performs against the virus in a laboratory setting.

Pfizer said these compounds could potentially be used in conjunction with another antiviral treatment being developed by Gilead Sciences GILD.O called remdesivir, which is further along in the development process."

Key notes

Pfizer's compounds use a different mechanism of action than Gilead's to attack the virus, Dolsten said, with Pfizer's looking to attack the protease segment of the virus.
The protease "is one of the best drug targets in the viral sector," Dolsten said. "It has been one of the most effective for HIV and HCV and our analysis confirmed that the COVID-19 protease target was very similar to one we had been working on for another virus."
Gilead CEO Daniel O'Day said that remdesivir is in late stage clinical trials in both China and the United States. He said the company should know "in the next couple of months" whether the drug helps treat patients with the coronavirus.

Author

Ross J Burland

FXStreet

Ross J Burland, born in England, UK, is a sportsman at heart. He played Rugby and Judo for his county, Kent and the South East of England Rugby team.

USD/JPY eyes August swing low, near 155.20 ahead of US NFP

USD/JPY retests the August monthly swing low during the Asian session on Friday as a more hawkish repricing of BoJ rate-hike bets and a suspected intervention continue to underpin the Japanese Yen. Meanwhile, the US Dollar is seen consolidating the previous day's heavy losses amid soft US bond yields, further weighing on the currency pair as traders keenly await the US NFP report.

AUD/USD consolidates above 0.7200; US NFP awaited

AUD/USD holds steady above 0.7200, near its highest level since mid-May, as bulls await the US NFP report for more cues on the Fed's policy path before placing fresh bets. Meanwhile, the recent decline in US bond yields keeps the US Dollar depressed near its lowest level in over a week and acts as a tailwind for the Aussie amid the RBA's hawkish tilt.

Gold bulls seem hesitant below $4,500 amid modest USD bounce ahead of US NFP

Gold remains on the defensive below the $4,500 mark through the Asian session, snapping a two-day winning streak amid a modest US Dollar uptick. The commodity, however, remains close to the weekly high, which it touched the previous day, as traders keenly await the release of the closely watched US monthly employment details. The popularly known US Nonfarm Payrolls (NFP) report will provide more cues about the Fed's policy path amid receding bets of a September rate hike.

Crypto’s $638 million buyback boom may not be as bullish as it looks

Decentralized Finance (DeFi) protocols reportedly spent $638 million to buy back their native tokens in August, up 17% from a year earlier. On the surface, the buyback trend suggests the cryptocurrency industry is maturing fast, adopting one of Wall Street’s oldest tools to bolster valuations and distribute revenue. The headline becomes less impressive once the number is opened up.

US August Nonfarm Payrolls expected to rebound to 56K after July slump

The US Bureau of Labor Statistics (BLS) is set to release the Nonfarm Payrolls (NFP) data for August. Investors expect NFP to rise by 56K in August following July’s unexpected print of -23K.

Diesel’s record $100 warning: The oil shock hiding in plain sight

The Oil market may look calmer than it did a few months ago, but diesel is sending a very different message. The US diesel crack spread, the premium of ultra-low sulphur diesel futures over WTI, recently surged above $100 per barrel for the first time, reaching an intraday record of just over $102.00.